Kennedy, Laura C. http://orcid.org/0000-0001-8958-7909
Wong, Kit Man
Kamat, Nikhil V.
Khaki, Ali Raza
Bhatia, Shailender
Thompson, John A.
Grivas, Petros
Article History
First Online: 24 July 2020
Compliance with Ethical Standards
:
: No funding was received for the preparation of this article. Training support for Laura C. Kennedy, Nikhil V. Kamat, and Ali Raza Khaki was provided by the National Cancer Institute (T32 CA009515).
: Laura C. Kennedy, Kit Man Wong, Nikhil V. Kamat, Ali Raza Khaki, and John A. Thompson have no conflicts of interest that are directly relevant to the content of this article. Shailender Bhatia reports advisory board participation (with honorarium) from Genentech, EMD-Serono, Bristol-Myers-Squibb (BMS), and Sanofi Genzyme and research funding to his institution (University of Washington) from Oncosec, EMD-Serono, Merck, BMS, NantKwest, Immune Design, Novartis, Nektar, and Exicure. Petros Grivas has conducted unrelated consulting with AstraZeneca, Bayer, Biocept, Bristol-Myers Squibb, Clovis Oncology, Driver, EMD Serono, Exelixis, Foundation Medicine, Genentech, Genzyme, GlaxoSmithKline, Heron Therapeutics, Janssen, Merck, Mirati Therapeutics, Pfizer, Seattle Genetics, QED Therapeutics, and Roche; and has received institutional research funding from AstraZeneca, Bayer, Genentech/Roche, Merck, Mirati Therapeutics, Oncogenex, Pfizer, Clovis Oncology, Bavarian Nordic, Immunomedics, Debiopharm, Bristol-Myers Squibb, Kure It Cancer Research, and QED Therapeutics (in the last 36 months).
: STUDY00008393.